Molecule Blog

MARCH 17, 2023

The university then licenses the IP to an existing pharmaceutical company or a biotech startup, which takes on Investigational New Drug (IND) enabling studies. This phase is typically executed by private biotech labs and/or contract research organizations, funded by venture capital and/or pharma balance sheets.

Engineering 52

Engineering Research Clinical Trials Government 52

The Pharma Data

NOVEMBER 19, 2020

Baffa joins the company from Medisix, where he held the role of Head of R&D and CMO. Previously, Baffa was Therapeutic Area Head of Oncology, Global Clinical Development for Shire. where he led the company’s operations during a period of rapid growth. Cogentus Pharmaceuticals, Inc., Affymetrix, Inc.,

Laboratories 52

Laboratories Research Laboratories Science Organic Chemistry 52

Agency IQ

FEBRUARY 12, 2024

The consortium is funded by a public-private partnership called the Accelerating Medicines Partnership (AMP) , through which the Foundation for the NIH (FNIH) administers funds provided by industry, government, and nonprofits to scientists working on applicable basic or clinical research to advance gene therapy development for rare diseases.

FDA 40

FDA Therapies Clinical Trials Disease 40

Vial

APRIL 10, 2024

The increasing costs associated with in-house drug development have prompted biotech and pharmaceutical companies to increasingly outsource to contract research organization s (CROs) for assistance. The company reported a revenue of $11,116 million for the first nine months of 2023, marking a 4.2%

Clinical Trials 52

Clinical Trials Trials Clinical Research Compliance 52

The Pharma Data

JANUARY 24, 2021

Sairiyo is a biotechnology company focused on repurposing and developing improved formulations of naturally derived compounds for serious, rare, and life-threatening diseases with the aim to obtain European Medicines Evaluation Agency and U.S. Toronto, Ontario–(Newsfile Corp. – January 25, 2021) – PharmaDrug Inc.

FDA 52

FDA Drugs Clinical Development Disease 52

The Pharma Data

OCTOBER 14, 2020

AOP Orphan – AOP Orphan Pharmaceuticals took over the Viennese pharmaceutical company Amomed and the Luxembourgish health-tech company SciPharm. AOP anticipates new opportunities in Austria as a hub for research and business. All jobs have been maintained and the workforce has grown from about 220 to 350.

Clinical Trials 52

Clinical Trials Trials Pharmaceuticals Therapies 52

Advarra

AUGUST 10, 2023

The Orphan Drug Act creates incentives for developing orphan drugs to treat such diseases. The FDA plans to launch Operation Warp Speed for Rare Diseases in 2023 with a focus on increased communication between the agency and drug and biotech companies. Research sites without access to an IBC may consider relying on a commercial IBC.

Drug Development 52

Drug Development Disease Therapies Engineering 52

The Pharma Data

OCTOBER 19, 2020

van de Laar has over 20 years of experience in biotechnology scale up and manufacturing and will be responsible for leading the Company’s preparations for commercial readiness, CMC activities and global supply chain management. Dr. Kraan joins AM-Pharma from Pierre Fabre S.A.,

Trials 40

Trials Small Molecule Cell Biology Clinical Trials 40

Drug Target Review

SEPTEMBER 5, 2024

I am a pharmacist by training and continued with a PhD in Clinical Pharmacology. However, my goal was all the time to work with drug development in the pharma industry, so I moved on and started that journey in 1992 when I took on a role as Clinical Research Manager at AstraHässle, a mid-size Swedish pharma company.

Pharma Companies 111

Pharma Companies Licensing Licensing Disease 111

The Pharma Data

JUNE 26, 2021

RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. About EXPLORER The EXPLORER clinical research program is unmatched by any oral anticoagulant in the Factor Xa inhibitor class in its size, scope and ambition.

Doctors 52

Doctors Treatment Hospitals Clinical Trials 52

The Pharma Data

JANUARY 14, 2021

Associate Professor of Medicine at UCLA, Co-director of the Gastrointestinal Oncology Program and Director of Early Phase Clinical Research at the Jonsson Comprehensive Cancer Center. This vision is what defines us and guides our research, clinical development and partnerships. Wainberg, M.D., Wainberg, M.D.,

Trials 52

Trials Treatment Therapies Clinical Trials 52

The Pharma Data

OCTOBER 27, 2020

Under the agreement, during the option period, Molecular Partners will conduct Phase 1 clinical trials for MP0420, expected to begin in November 2020, and perform all remaining preclinical work for MP0423 and Novartis will conduct Phase 2 and Phase 3 clinical trials, with Molecular Partners as sponsor of these trials.

Therapies 40

Therapies Virus Treatment Clinical Trials 40